The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

• ClinicalTrials.gov Identifier: NCT00115895
• Recruitment Status: Unknown
• First Posted: June 27, 2005
• Last Update Posted: March 2, 2018
• Sponsor: University of Helsinki
• Collaborator: Helsinki University Central Hospital
• Information provided by (Responsible Party): Hanna Mäenpää, University of Helsinki

Study Description

Brief Summary:

The thyroid cells take up iodine, and radioactive iodine is commonly used to irradiate residual thyroid tissue and thyroid cancer following surgical removal of the thyroid gland (thyroidectomy). A whole body radioactive iodine scanning is usually carried out after thyroidectomy to assess the amount of thyroid tissue left behind at surgery (that might still contain cancer), and to evaluate the presence of iodine avid lesions elsewhere in the body (that might be cancer metastases). A large dose of radioactive iodine is often given, still the optimal iodine dose to ablate the thyroid remnant after surgery is not known. In this study, two radioactive iodine doses are compared in the ablation of the thyroid remnant, a smaller (1110 MBq) dose and a larger (3700 MBq) dose. The study participants are randomly allocated using a 1:1 ratio to receive either the smaller or the larger radioactive iodine dose. These treatments are compared for safety, adverse effects, and the need for subsequent repeat treatments. The individual absorbed radiation doses are measured. The study hypothesis is that fewer repeat radioiodine treatments might be needed after the larger dose, but the larger dose might be associated with a higher frequency of adverse events.

Condition or disease	Intervention/treatment	Phase
Thyroid Neoplasms	Drug: Radioactive iodine	Phase 3

Detailed Description:

The study participants are randomly allocated to receive either a 1110 MBq or a 3700 MBq dose of radioiodine (131I) approximately 5 weeks after thyroidectomy. Thyroxin substitution is initiated only after administration of radioactive iodine. Treatment efficacy is monitored using serum thyroglobulin measurements and whole body radioiodine scanning. The absorbed radiation dose at the thyroid remnant and the biological half-life of radioactive iodine are measured with SPECT, 131I iodine detector and a Geiger counter.

Treatment related adverse events are collected using structured forms 4 to 5 days, 2 weeks and 3 months after administration of radioiodine. The need for a repeat treatment is assessed 4 to 6 months after the first administration of radioiodine. The criteria for a repeat radioiodine treatment are serum thyroglobulin > 1 ug/L and/or presence of abnormal radioiodine uptake in a whole body radioiodine scanning, which is carried out following a 4-week interruption of thyroxin supplementation or following administration of rhTSH.

Number of patients: 160

Aims of the study:

• To find out weather the risk for second radioiodine treatment differs with two dose levels of radioiodine: 1110 MBq or 3700 MBq.
• To study possible differences in the adverse effects in the treatment groups. Also days at hospital are counted.
• To analyse the effect of absorbed radiation dose to the treatment results

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 160 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq
• Study Start Date: January 2000
• Actual Primary Completion Date: October 2004
• Estimated Study Completion Date: September 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Radioactive iodine 1,1 GBq; Low activity of radioiodine, 1,1 GBq	Drug: Radioactive iodine; Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq; Other Name: radioiodine
Radioactive iodine 3,7 GBq; Routine activity of radioiodine, 3,7 GBq	Drug: Radioactive iodine; Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq; Other Name: radioiodine

Outcome Measures

Primary Outcome Measures :

1. Cumulative number of radioactive iodine administrations [ Time Frame: 15 yrs ]

Secondary Outcome Measures :

1. Adverse events [ Time Frame: 15 yrs ]
2. Absorbed radiation dose [ Time Frame: 15 yrs ]
3. Cancer recurrence [ Time Frame: 15 yrs ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

• Total or near total thyroidectomy performed for papillary or follicular thyroid cancer
• R0-1 resection, no macroscopic cancer left behind at surgery
• Physically and emotionally able to undergo radioiodine treatment
• A written informed consent

Exclusion criteria:

• Pregnancy
• Physical or psychiatric illness that may deteriorate during the isolation period required by radioiodine therapy

Contacts and Locations

Locations

Finland

Helsinki University Central Hospital, Department of Oncology

Helsinki, Finland, FIN-00029HUS

Sponsors and Collaborators

University of Helsinki

Helsinki University Central Hospital

Investigators

• Principal Investigator: Hanna O Mäenpää, M.D. Ph.D.; Deputy Chief Physician

More Information

Additional Information:

Helsinki University Central Hospital 

Publications:

Roos DE, Smith JG. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique. Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):493-5. Review.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One. 2008 Apr 2;3(4):e1885. doi: 10.1371/journal.pone.0001885.

• Responsible Party: Hanna Mäenpää, Chief of Department, University of Helsinki
• ClinicalTrials.gov Identifier: NCT00115895
• Other Study ID Numbers: SYTJ001T/2000
• First Posted: June 27, 2005
• Last Update Posted: March 2, 2018
• Last Verified: March 2018

Keywords provided by Hanna Mäenpää, University of Helsinki:

radioiodine; serum thyroglobulin; whole body radioiodine scanning

Additional relevant MeSH terms:

Thyroid Neoplasms; Thyroid Diseases; Endocrine System Diseases; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms